Arkolith/Insider Trading/AURA/Form 4

Feder Julie B

Chief Financial OfficerAura Biosciences, Inc. (AURA) · full profile →Form 4 · filed Oct 21, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$302K
Net Open-Market Flow
-$302K
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 18, 2024Sell(S)25K$12.03$302K134K
Oct 18, 2024Option exercise(M)18K$2.74$48K152K
Oct 18, 2024Option exercise(M)3K$4.25$11K154K
Oct 18, 2024Option exercise(M)5K$5.48$27K159K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 18, 2024Option exercise(M)18K—$068K
Oct 18, 2024Option exercise(M)5K—$0121K
Oct 18, 2024Option exercise(M)3K—$032K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-116029) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML